Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 14/20 | 0.76 |
| ▸ | KDM6B | O15054 | 6/20 | 0.51 |
| ▸ | KDM4D | Q6B0I6 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | KDM4A | O75164 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31574278 | 0.86 | KDM4C (1.00) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL15295159 | 0.86 | KDM4C (1.00) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL188821 | 0.84 | KDM4C (0.55) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL9616247 | 0.84 | KDM4C (0.55) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL12990781 | 0.84 | KDM4C (0.59) | KDM4CKDM6BKDM4ETDP1ALDH1A1 | |
| SCHEMBL19611328 | 0.84 | KDM4C (0.55) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL31563528 | 0.84 | KDM4C (0.59) | KDM4CKDM6BKDM4ETDP1ALDH1A1 | |
| SCHEMBL4429003 | 0.83 | KDM4C (0.54) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL31620734 | 0.83 | KDM4C (0.54) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| Acetone SCHEMBL2032550 | 0.83 | KDM4C (0.54) | KDM4CKDM6BKDM4DKDM4EKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10618898-B2 | Hydroxyl purine compounds and use thereof | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2020-04-14 | — | — | US | disclosed |
| EP-3558307-A1 | 6,6-FUSED HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | Merck Sharp & Dohme Corp. (US) | 2019-10-30 | — | — | EP | disclosed |
| US-10278973-B2 | Hydroxyl purine compounds and use thereof | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-05-07 | — | — | US | disclosed |
| WO-2018118735-A1 | 6,6-FUSED HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20180148451-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2018-05-31 | — | — | US | disclosed |
| US-20180148451-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2018-05-31 | — | — | US | disclosed |
| US-20180140607-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2018-05-24 | — | — | US | disclosed |
| EP-3299371-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-28 | — | — | EP | disclosed |
| EP-3299371-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-28 | — | — | EP | disclosed |
| CN-107709323-A | Oxipurinol class compound and its application | 广东众生药业股份有限公司 | 2018-02-16 | — | — | CN | disclosed |
| EP-2776417-A1 | 5-(PYRIDIN-2-YL-AMINO)-PYRAZINE-2-CARBONITRILE COMPOUNDS AND THEIR THERAPEUTIC USE | Cancer Research Technology Limited (GB) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013068755-A1 | 5-(PYRIDIN-2-YL-AMINO)-PYRAZINE-2-CARBONITRILE COMPOUNDS AND THEIR THERAPEUTIC USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-05-16 | — | — | WO | disclosed |
| EP-2097416-A1 | AZAQUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | Amgen, Inc (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20080269214-A1 | Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| WO-2008076425-A1 | AZAQUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| US-7361760-B2 | Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases | AVANIR PHARMACEUTICALS (US) | 2008-04-22 | — | — | US | disclosed |
| EP-1861393-A2 | PYRROLE DERIVATIVES AS DNA GYRASE AND TOPOISOMERASE INHIBITORS | AstraZeneca AB (SE) | 2007-12-05 | — | — | EP | disclosed |
| US-20070191388-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2007-08-16 | — | — | US | disclosed |
| WO-2006092599-A2 | PYRROLE DERIVATIVES AS DNA GYRASE AND TOPOISOMERASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-09-08 | — | — | WO | disclosed |
| WO-1995007909-A1 | ALKYL-1-ALKYL-4-HYDROXY-2-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLATES AS ANTI-RHEUMATIC AGENTS | KNOLL AG (DE) | 1995-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191388-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | MIF, MSR1, SLC11A2 | KDM4C 3875/4885KDM6B 4137/4885KDM4D 3289/4885 |
| US-20180148451-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | PNP, PDE7A, PDE2A | KDM4C 3752/4885KDM6B 2397/4885KDM4D 3627/4885 |
| US-10618898-B2 | Hydroxyl purine compounds and use thereof | PNP, PDE7A, PDE2A | KDM4C 3752/4885KDM6B 2397/4885KDM4D 3627/4885 |
| US-20180140607-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | PNP, PDE7A, PDE2A | KDM4C 3698/4885KDM6B 2373/4885KDM4D 3609/4885 |
| US-10278973-B2 | Hydroxyl purine compounds and use thereof | PNP, PDE7A, PDE2A | KDM4C 3698/4885KDM6B 2373/4885KDM4D 3609/4885 |
| US-20080269214-A1 | Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors | TOP1, TOP2A, TOP2B | KDM4C 2493/4885KDM6B 1707/4885KDM4D 2288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.